-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5207 Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time

Program: Oral and Poster Abstracts
Session: 909. Education, Communication, and Workforce: Poster III
Hematology Disease Topics & Pathways:
Workforce, Diversity, Equity, and Inclusion (DEI), Education
Monday, December 9, 2024, 6:00 PM-8:00 PM

James Troyer, MD1*, Bonnie Lu2*, Kathryn Krause3*, Melanie Aviles4*, Sherraine Della-Moretta, MD5, Dre'Von Dobson, PhD6*, Kaveh Farrokhi7*, Zainul S. Hasanali, MD, PhD8, Ajibike Lapite, MD, MPH9, Pallavi Pillai, MD10, Cristian Taborda, MD11*, Lynda Villagomez, MD12, Phuong T Vo, MD13,14, Ruth Wang’ondu15*, Jennifer C. Yui, MD, MSc16, Angela C Weyand, MD17 and Warren B. Fingrut, MD18*

1University of Texas MD Anderson Cancer Center, Houston, TX
2Michael G. DeGroote School of Medicine, Hamilton, ON, Canada
3Research Medical Library, University of Texas MD Anderson Cancer Center, Houston, TX
4Jacobi Medical Center, Bronx, NY
5Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
6Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC
7Department of Family Medicine, University of Ottawa, Ottawa, ON, Canada
8Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
9Division of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine / Texas Children’s Hospital, Houston, TX
10Merck & Co., Inc., Rahway, NJ
11Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
12Department of Pediatrics, Division of Hematology and Oncology, The Ohio State University and Nationwide Children's Hospital, Columbus, OH
13Division of Oncology, University of Washington, Seattle, WA
14Fred Hutchinson Cancer Center, Shoreline, WA
15Department of Pathology and Oncology, St Jude Children's Research Hospital, Memphis, TN
16Johns Hopkins University School of Medicine, Baltimore, MD
17Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI
18Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Introduction: Health equity is increasingly being recognized as a critical priority across medicine. Through an initiative of the ASH Health Equity Task Force, we recently published the ASH Health Equity Compendium (Fingrut et al, Blood Adv. 2024) to describe/catalogue the health equity manuscripts published across the Blood journals. Extending from this work, herein we report the results of a scoping review of health equity in hematology. We aimed to gather published articles together to highlight hematology health equity works, note areas that would benefit from more attention and inspire efforts to spearhead projects characterizing/addressing disparities.

Methods: We applied PRISMA-P extension guidelines to develop/publish a scoping review protocol, https://osf.io/exuzc. Articles were eligible if focused on health equity in hematology and published in one of 22 hematology journals 1/1/18-3/13/24 or 46 oncology/medicine/pediatrics journals 1/1/18-4/4/24 which had an impact factor >9.2 or were listed in Clarivate’s Journal Citation Reports first quartile or were a major hematology/oncology society’s official journal. A research librarian crafted a search to retrieve all articles with ≥1 health equity subject heading or ≥1 title/abstract health equity keyword from a predefined list. Articles underwent title/abstract then full text review and data extraction by 2 independent team members. All extracted data were published to docs.google.com/spreadsheets/d/1rFeGrNVdIDnYEzL9KPB1rqyZUafWGcoN11FsKGUzyCY.

Results: The search returned 5,494 articles; 1,009 underwent full-text screening with 602 included in the review. The greatest number of articles were published in Pediatric Blood & Cancer (n=77) and Blood Advances (n=65), with the highest proportions in Lancet Haematology (3.3%) and Transplantation and Cellular Therapy (3.1%).

Most articles were about patients, with 64 (11%) about blood/stem cell donors and 26 (4%) the workforce. 132 (22%) had a pediatric/adolescent/young adult focus. 262 (44%) were retrospective studies, with 116 (19%) prospective/trials and 23 studying basic science correlates of disparities. Only 64 (11%) described interventions to advance equity, 20 (3%) social determinants of health data collection process improvement and 1 health equity educational initiatives. Of 427 research articles (ie excluding 175 editorials/reviews), nearly half (204/427, 48%) reported disparities in disease phenotype/outcomes, with 69/427 (16%) on access to care.

Of 562 disease-related articles, most (372/562, 66%) examined hematologic malignancies or BMT/cell therapy with only one third (190/562, 34%) about classical hematologic conditions.

Most articles (342/602, 57%) focused on racial/ethnic disparities, with 239 (40%) on socioeconomics; 87 (14%) sex/parity; 65 (11%) geographic; 54 (9%) age; and 46 (8%) sexual/gender minorities (22 on transgender peoples). Less than a third (179/602, 30%) considered intersectionality across disparities. Only 12 focused on Indigenous peoples, 5 disability, 8 religion, 9 immigration and 2 incarceration. Only 8 noted partnerships with the populations impacted.

Analyzing by year from 2018-2023, health equity articles increased over time, with nearly two thirds (356/545, 65%) of included articles published 2021-2023 versus one third (189/545, 35%) 2018-2020, p<.001. Focusing on the 22 included hematology journals, 491 health equity articles were published 2018-2023, reflecting 1.1% of all articles published in those journals over these years. Hematology journals also had a 75% increase in the proportion of health equity articles in the recent vs earlier periods (0.8% vs 1.4%, p<.001).

Conclusion: Our analysis, the first of its kind to our knowledge, highlights recent progress characterizing inequities and clarifies areas warranting further study (eg disparities impacting understudied populations with consideration of intersectionality, across classical and malignant hematologic disorders, and testing interventions to address disparities, partnering with advocates from populations impacted). We also establish benchmarks for the proportion of health equity articles published, within/across journals. This review will serve as an important educational resource to advance equity, helping researchers and the field in general to assimilate the rapidly expanding hematology health equity literature

Disclosures: Pillai: Merck & Co., Inc.: Current Employment, Current holder of stock options in a privately-held company. Weyand: Pfizer: Research Funding; Octapharma: Honoraria; Novo Nordisk: Honoraria, Research Funding; Genentech: Honoraria; Sanofi: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Hemab: Consultancy; Biomarin: Honoraria; Bayer: Honoraria.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH